Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE
4
Issued Date
2023-09-12
Resource Type
ISSN
24739529
eISSN
24739537
Scopus ID
2-s2.0-85171637533
Pubmed ID
36103340
Journal Title
Blood Advances
Volume
7
Issue
17
Start Page
4773
End Page
4781
Rights Holder(s)
SCOPUS
Bibliographic Citation
Blood Advances Vol.7 No.17 (2023) , 4773-4781
Suggested Citation
Wong R.S.M., Yavaşǒglu I., Yassin M.A., Tarkun P., Yoon S.S., Wei X., Elghandour A., Angchaisuksiri P., Ozcan M., Yang R., Mattar M., Rahman M., Ingles S., Goldbrunner M., Frueh J.A., Jang J.H. Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE. Blood Advances Vol.7 No.17 (2023) , 4773-4781. 4781. doi:10.1182/bloodadvances.2022008287 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/90225
Title
Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE
Author's Affiliation
Ramathibodi Hospital
Chinese Academy of Medical Sciences & Peking Union Medical College
Hamad Medical Corporation
Kocaeli Üniversitesi
Prince of Wales Hospital Hong Kong
Faculty of Medicine
Adnan Menderes Üniversitesi
Faculty of Medicine
Samsung Medical Center, Sungkyunkwan university
Dokuz Eylül Üniversitesi
Guangzhou Medical University
Novartis International AG
Seoul National University College of Medicine
Chinese Academy of Medical Sciences & Peking Union Medical College
Hamad Medical Corporation
Kocaeli Üniversitesi
Prince of Wales Hospital Hong Kong
Faculty of Medicine
Adnan Menderes Üniversitesi
Faculty of Medicine
Samsung Medical Center, Sungkyunkwan university
Dokuz Eylül Üniversitesi
Guangzhou Medical University
Novartis International AG
Seoul National University College of Medicine
Other Contributor(s)
Abstract
CITE was a prospective, noninterventional study in adult patients with chronic immune thrombocytopenia treated with eltrombopag under routine clinical care in Asia-Pacific, the Middle East, and Turkey. Data to assess eltrombopag usage, compliance, and outcomes were collected from May 2017 to December 2020. Platelet response was defined as platelet count ≥50 × 103/μL in the absence of rescue medications and splenectomy. Quality of life was evaluated using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire. Noncompliance was defined as the number of missed doses and number of days where the patient did not follow food instructions. A total of 231 patients were enrolled; the median (range) duration of eltrombopag treatment was 484.5 (1-642) days. Compliance to prescribed eltrombopag dose since the previous routine visit was high at ≥96.0%. Baseline median platelet count was 19.0 × 103/μL, which increased to ≥50 × 103/μL at month 2 and mostly fluctuated between 70 × 103/μL and 100 × 103/μL thereafter. The median time to first platelet response was 1.05 (95% confidence interval: 0.92-1.28) months, and the median (interquartile range) maximum duration of platelet response was 193 (57-456) days. FACIT-F scores improved from a mean (standard deviation) 34.4 (12.1) at baseline to 38.5 (9.1) at month 18. Adverse events occurred in 50.9% of patients (n = 116), the most common being upper respiratory tract infection (8.3%) and headache (6.6%). These findings confirmed the effectiveness of eltrombopag treatment in routine practice and reassured that real-world compliance to eltrombopag-prescribed doses and dietary instructions in Asia-Pacific, the Middle East, and Turkey were in line with current recommendations.